The CB1 receptor allosteric modulator Org27569 was shown to act as an inverse agonist of ERK signaling, reducing baseline activity and blocking CB1 receptor internalization triggered by synthetic cannabinoids.
Read this if you follow cannabinoid receptor pharmacology research or are interested in how allosteric modulators might lead to next-generation cannabinoid medicines.
First demonstration of ERK inverse agonism by a CB1 allosteric modulator
What the researchers found
Allosteric modulators bind to a different site on a receptor than the primary binding site, offering a way to fine-tune receptor activity rather than simply turning it on or off. Org27569 is the most-studied allosteric modulator of the CB1 cannabinoid receptor.
This study resolved conflicting reports about how Org27569 affects ERK signaling, a key pathway through which cannabinoid receptors influence cell behavior. The researchers found that Org27569 fully blocked ERK activation triggered by the synthetic cannabinoid CP55,940 but could not completely block ERK activation by THC or 2-AG (the body's own cannabinoid).
Org27569 also reduced baseline ERK activity below normal levels, an effect mediated specifically through CB1 receptors and their associated G-proteins. This is the first demonstration of ERK inverse agonism by Org27569.
Why it matters
Allosteric modulators represent a frontier in cannabinoid drug development because they could theoretically dial cannabinoid receptor activity up or down without the all-or-nothing effects of current drugs. Understanding exactly how Org27569 affects signaling pathways is essential for developing this approach into practical therapies.
The numbers in context
CP55,940 (1 uM) produced significant receptor internalization at 20, 40, 60, and 120 minutes. Org27569 (10 uM) fully prevented this internalization. Org27569 reduced basal ERK phosphorylation in CB1-expressing cells but not untransfected cells. Effects were observed in both nuclear and cytosolic cell fractions.
How the study worked
Cell-based experiments using HEK293 cells expressing human CB1 receptors. Researchers measured G-protein activation, ERK phosphorylation, receptor internalization via confocal imaging, and subcellular fractionation to determine where in the cell ERK changes occurred. Pertussis toxin was used to confirm the role of Gi/o proteins.
What this study cannot tell us
All experiments were in cell cultures overexpressing CB1 receptors, which may not reflect receptor behavior in living brains. The concentrations used may not be achievable in vivo. The clinical relevance of ERK inverse agonism at CB1 receptors remains to be determined.
How to read the evidence
Rigorous cell-based mechanistic study with multiple confirmatory approaches, but entirely in vitro with no clinical relevance established.
When this study was published
Published in 2016. Allosteric modulator research has continued to evolve since.
The bigger picture
Most current cannabinoid drugs work by directly activating or blocking CB1 or CB2 receptors. Allosteric modulators represent a fundamentally different approach that could allow more nuanced control of the endocannabinoid system, potentially reducing side effects while preserving therapeutic benefits.
Questions still open
- Could allosteric modulators like Org27569 or its derivatives be developed into practical treatments? Why does Org27569 fully block CP55,940 but not THC-mediated ERK signaling?
Common questions
What is an allosteric modulator?
Why is this finding important for drug development?
Read the original research
CB1 allosteric modulator Org27569 is an antagonist/inverse agonist of ERK1/2 signaling.
Cannabis and cannabinoid research, 1(1), 272-280
Citation
Gamage, Thomas F; Anderson, Johnathon C; Abood, Mary E. (2016). CB1 allosteric modulator Org27569 is an antagonist/inverse agonist of ERK1/2 signaling.. Cannabis and cannabinoid research, 1(1), 272-280. https://doi.org/10.1089/can.2016.0028
Explore the wider topic
- How THC Affects Your Amygdala: The Brain's Threat Detector and Cannabis
- The Anandamide Connection: Your Body's Natural Bliss Molecule
- How Long for Cannabinoid Receptors to Return to Normal
- Cannabis and the Developing Brain: What Every Teenager (and Parent) Should Know
- Why Can't I Enjoy Anything Without Weed? The Science Behind It
- Dopamine Recovery After Quitting Weed: What the Science Says
- The Endocannabinoid System Explained Simply: What It Does and Why It Matters
- Your Endocannabinoid System Explained: Why Withdrawal Happens
- Your Nervous System After Quitting Weed: Fight or Flight
- Using Weed Under 18: What It Does to Your Developing Brain
- What THC Does to Your Brain: Why Withdrawal Happens
- THC and Your Prefrontal Cortex: What Cannabis Does to Your Decision-Making Brain
- Weed, Cortisol, and Stress: What Cannabis Does to Your Stress Hormones
- Weed and Memory: What the Science Says About THC and Your Hippocampus
- Weed and Motivation: Is Amotivational Syndrome Real?
- Weed and Your Nervous System: What THC Actually Does to Your Brain and Body
- How Weed Rewires Your Reward System (And How to Reset It)